SUPRACOR™ Advisor против Biotech Calculators Использование & Stats

With the B+L SUPRACOR™ Advisor app, you can get laser treatment recommendations according to various patient’s profiles. Ease your daily refractive workflow using SUPRACOR™! Start by selecting the visual condition that you want to treat. After, you will have to indicate: - Patient Expectation - Spherical equivalent (D) - Keratometry (D) Bausch + Lomb SUPRACOR™ Advisor app will provide you with generic treatment pathways: mild, regular and strong. The SUPRACOR™ Advisor is recommending options based on standard estimates only. The surgeon develops their own decision and is responsible for patient outcomes. Please note that any information provided is not a substitute for professional medical advice. This app is intended for use by Surgical Professionals or in conjunction with a Surgical Professional.
  • Apple App Store
  • Бесплатный
  • Медицина

Рейтинг магазина

- -

Biotech Calculators Mobile app: Download mobile app Biotech Calculators to calculate Eyecryl Toric as well as Eyecryl Actv Toric IOLs for your patients. Simply enter the patient’s pre-op data in your desired Eyecryl IOL option and get the precise IOL model for your patient. Biotech Calculators is designed to help eye care practitioners to serve with precise IOL calculations to provide best patient out come after cataract surgery. Once the application is downloaded and logged in, it works offline as well.
  • Apple App Store
  • Бесплатный
  • Медицина

Рейтинг магазина

- -

SUPRACOR™ Advisor vs. Biotech Calculators ranking comparison

Compare SUPRACOR™ Advisor ranking trend in the past 28 days vs. Biotech Calculators

Rank

Нет данных

Рейтинг SUPRACOR™ Advisor против Biotech Calculators в сравнении по странам

Сравните динамику рейтинга SUPRACOR™ Advisor за последние 28 дней с динамикой рейтинга Biotech Calculators.

Нет данных для отображения

Сравните данные с любым сайтом, воспользовавшись бесплатной пробной версией

Начать
SUPRACOR™ Advisor VS.
Biotech Calculators

декабрь 25, 2024